MAZE

Maze Therapeutics, Inc. Common Stock

MAZE

Market cap $1.03B

Overview Fund Activity

23.46 USD

+0.21

0.9%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

23.40

-0.06

0.26%

1 day

0.9%

5 days

43.84%

1 month

75.73%

3 months

76.26%

6 months

104.18%

Year to date

47.08%

1 year

47.08%

5 years

47.08%

10 years

47.08%

About: Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Employees: 125

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

79% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 14

9% more funds holding

Funds holding: 68 [Q1] → 74 (+6) [Q2]

8% more capital invested

Capital invested by funds: $441M [Q1] → $477M (+$35.3M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 8 [Q1] → 8 (+0) [Q2]

2.78% less ownership

Funds ownership: 91.45% [Q1] → 88.67% (-2.78%) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

28% downside

Avg. target

$35

47% upside

High target

$50

113% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Guggenheim Debjit Chattopadhyay	$34	Buy Maintained	15 Sep 2025
HC Wainwright & Co. Ananda Ghosh	$50	Buy Maintained	12 Sep 2025
BTIG Julian Harrison	$37	Buy Maintained	12 Sep 2025
Wedbush Laura Chico	$17	Outperform Initiated	8 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about MAZE published over the past 30 days

Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript)

Maze Therapeutics, Inc. (NASDAQ:MAZE ) MZE782 Phase 1 Healthy Volunteer Trial Results Conference September 11, 2025 08:30 AM ET Company Participants Amy Bachrodt Jason Coloma - CEO & Director Harold Bernstein - President of Research & Development and Chief Medical Officer Misbah Tahir - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Presentation Operator Good morning.

Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript)

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

Maze Therapeutics, Inc. MAZE on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

Investors Business Daily

Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results

Maze Therapeutics catapulted Thursday after its experimental treatment for a rare, genetic disease blew past the company's own expectations.

Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million, before deducting placement agent fees and other expenses.

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately.

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry. Following a challenge brought by Vertex Pharmaceuticals Incorporated, BBB National Programs' National Advertising Division will refer claims made by Maze Therapeutics, Inc. to the appropriate regulatory authorities for review and possible enforcement action for failure to submit a substantive response to the National Advertising Division's (NAD) inquiry.

National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that company management will participate in fireside chats during two upcoming investor conferences in July: H.C.

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D.

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™